Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07246187 · ClinicalTrials.gov registry record · Phase 3
Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department
A Phase 3 study of Cannabinoid Hyperemesis Syndrome, sponsored by Mercy Bon Secours Saint Vincent Medical Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 114
- Enrollment target
- 1
- Study location
NCT07246187 is a Phase 3 study of Cannabinoid Hyperemesis Syndrome that is actively recruiting participants, run by Mercy Bon Secours Saint Vincent Medical Center. The registered enrollment target is 114 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07246187, a Phase 3 study of Cannabinoid Hyperemesis Syndrome, is actively recruiting participants, sponsored by Mercy Bon Secours Saint Vincent Medical Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 114 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of the study is to identify which medication (haloperidol or olanzapine) is most effective in treating nausea and abdominal pain associated with cannabinoid hyperemesis using a 10-point visual analog scale with intervals of 0.5.
Conditions Studied
Interventions
- DRUG Olanzapine 10 milligram
- DRUG Haloperidol
Study Locations (1)
Ohio
- Mercy Saint Vincent Medical Center - Toledo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2025-11-06 |
| Est. Completion | 2026-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07246187
The ClinicalTrials.gov registry entry for NCT07246187 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mercy Bon Secours Saint Vincent Medical Center, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cannabinoid Hyperemesis Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Olanzapine 10 milligram is the first listed.
NCT07246187 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT07246187 about?
NCT07246187 is a clinical study titled "Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department". The aim of the study is to identify which medication (haloperidol or olanzapine) is most effective in treating nausea and abdominal pain associated with cannabinoid hyperemesis using a 10-point visual analog scale with intervals of 0.5.
What is the current status of trial NCT07246187?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 114 participants. The study started on 2025-11-06. Estimated completion is 2026-11.
What conditions does trial NCT07246187 study?
This clinical trial studies the following conditions: Cannabinoid Hyperemesis Syndrome.
What interventions are being tested in trial NCT07246187?
The interventions under investigation include: Olanzapine 10 milligram (DRUG), Haloperidol (DRUG).
Who is sponsoring clinical trial NCT07246187?
This trial is sponsored by Mercy Bon Secours Saint Vincent Medical Center, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07246187 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.